CSO QA_FA7013-20-S-0002_20Jul20.pdf

Date Area of Interest Question Government Response

7/17/2020 4-Pharma

Are all Solution Briefs for the Pharmaceutical Industrial Base Expansion AOI due by 12pm EDT 8/3/2020? Or are they accepted until 8/15/20?

Solution Briefs will be accepted until 12:00PM EDT; 3 Aug 20202

7/17/2020 4-Pharma

The Pharmaceutical Industrial Base Expansion AOI document states this request is in support of the HHS/ASPR priorities.

What role will HHS/ASPR play in reviewing Solution Briefs?

The Department of the Air Force Acquisition Task Force (DAF ACT) combined with the Joint Acquisition Task Force (JATF) will lead rapid solicitation and execution of contracts in support of the JATF mission. The Government will evaluate Solution Briefs against criteria stated in this CSO.

7/17/2020 4-Pharma

Is the Pharmaceutical Industrial Base Expansion AOI open to partnered solutions? If so, how should the partner organization be identified in the proposal?

CSO Paragraph 1.6.1.1. Small Business and Domestic Sourcing, section (a) states: During Spiral 1 Solution Briefs and Spiral 2, Oral Presentation, offerors shall identify their small business size and socio-economic status, as well as small business size and socio-economic status of any proposed team members or subcontractors under the NAICS identified in this paragraph or the NAICS the offeror believes would be appropriate pursuant to FAR 52.219-1, Small Business Program Representations (February 2020). CSO Paragraph 1.6.2 Spiral 1 identifies the Solution Brief Content.

7/17/2020 4-Pharma

Are organizations with previous government contracting experience preferred for the Pharmaceutical Industrial Base Expansion AOI?

CSO Paragraph 1.6.3. Spiral 1 Solution Brief and Paragraph

1.6.9. Spiral 3 CSP both provide the Basis of Evaluation for each Spiral.

7/20/2020 1- Masks Will the USG be willing to fund real estate improvement under the solicitation?

As long as it ties directly to Industrial Base Expansion, it meets the general requirements of the AOI.

7/20/2020 4-Pharm

Please confirm the 100M Unit figure listed in the AoI #04 General Information/Expansion Request. For API specifically, are you asking for enough API to manufacture 100M doses of finished medicinesfor each proposed API? For example, if Midazolam and Succinylcholine are two proposed APIs of interest, we should propose enough API volume to manufacture 100M doses (e.g. vials, etc.) of Midazolam and 100M doses (e.g. vials, etc.) of Succinylcholine?

Yes. The offeror should provide solutions that support 100M units of each Pharma Product included in its Solution Briefing.

Specifically, include enough KSM and/or API that supports the manufacturing of 100 million final dosage forms for each of the proposed products.

Sheet1